RxDoctor Payments Data

James Yeager

Family · Bella Vista, ARNPI 1922630367

Payments from drug & device makers

$6,713in general payments, 2019–2025

Across 387 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$986
  • GSK$665
  • Pfizer$529
  • AstraZeneca$526
  • Amgen$472
  • Novo Nordisk$344
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,713100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,713 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$73,772
Medicare patients
298
Services billed
2,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin41$38,903
EliquisApixaban36$35,419
FarxigaDapagliflozin Propanediol33$31,878
OzempicSemaglutide16$26,197
XareltoRivaroxaban18$23,866
MounjaroTirzepatide21$21,764
LinzessLinaclotide13$8,762
Breo ElliptaFluticasone/Vilanterol17$8,701
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,271
BelsomraSuvorexant11$5,003
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,085
Omeprazole88$1,345
Atorvastatin Calcium200$1,279
Tamsulosin Hcl47$1,053
Albuterol Sulfate HfaAlbuterol Sulfate49$990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$526$40,14946 claims
Boehringer IngelheimJardiance$163$38,90341 claims
PfizerEliquis$529$35,41936 claims
Novo NordiskOzempic$344$26,19716 claims
Johnson & JohnsonXarelto$180$23,86618 claims
Lilly USA, LLCMounjaro$323$21,76421 claims
AbbVieLinzess$986$8,76213 claims
GSKBreo Ellipta$665$8,70117 claims
MerckBelsomra$69$5,00311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.

Other family in Bella Vista

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →